The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is
a lateral flow immunoassay intended for the qualitative detection and differentiation
of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood, plasma
from anticoagulated blood (Li+ heparin, K2EDTA and sodium citrate), or
serum. The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)
is intended for use as an aid in identifying individuals with an adaptive immune
response to SARS-CoV-2, indicating recent or prior infection. At this time, it is
unknown for how long antibodies persist following infection and if the presence of
antibodies confers protective immunity. The COVID-19 IgG/IgM Rapid Test
Cassette (Whole Blood/Serum/Plasma) should not be used to diagnose acute
SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform
moderate or high complexity tests.
Results are for the detection of SARS CoV-2 antibodies. IgM and IgG antibodies to
SARS-CoV-2 are generally detectable in blood several days after initial infection,
although the duration of time antibodies are present post-infection is not well
characterized. Individuals may have detectable virus present for several weeks
following seroconversion.
Laboratories within the United States and its territories are required to report all
positive results to the appropriate public health authorities.
The sensitivity of COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) early after infection in unknown. Negative results do not
preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing
for SARS-CoV-2 is necessary.
False positive results for COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) may occur due to cross-reactivity from pre-existing
antibodies or other possible causes. Due to the risk of false positive results,
confirmation of positive results should be considered using second, different IgG or
IgM assay.
The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is only
for use under the Food and Drug Administration’s Emergency Use Authorization.
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyHK HuZef
1. Accuracy
1.1 Purpose
To evaluate the equivalence of COVID-19 IgG/IgM Rapid Test result and clinical diagnosis.
1.2 Method
By testing clinical samples with known results, to evaluate the accuracy of COVID-19 IgG/IgM
Rapid Test (Whole blood/Serum/Plasma).
1.3 Material
COVID-19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma)
Cassette Lot1: 2002155,Lot2:2002156,Lot3:2002157
Clinical samples
1.4 Test Procedure
1) Prepare specimens: tests were taken to clinical partner to evaluate, totally 113 specimens.
2) Perform the test according to the test procedure in the package insert
1.5 Result
1) IgM
Risk Analysis of igg/igm Rapid Test Kits by healgenHK HuZef
1. Introduction
1.1. Overview
This document provides a safety risk analysis for COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma).
1.2. Intended Use/Purpose
COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a solid phase immunochromatographic
assay for the rapid, qualitative and differential detection of IgG and IgM antibodies to 2019 Novel Coronavirusi in
human whole blood, serum or plasma. This test provides only a preliminary test result. Therefore, any reactive
specimen with the COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) must be confirmed
with alternative testing method(s) and clinical findings.
1.3. Scope
This risk analysis addresses the safety risks that may affect the patient or the operator as associated with the
operation of the COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma).
This document provides a safety risk analysis for COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma), which references the standard of ISO 14971:2012.
buy Healgen Antibody IgG/IgM rapid test kitsHK HuZef
COVID-19 IgG/IgM Rapid Test
COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a solid
phase immunochromatographic assay for the rapid, qualitative and differential
detection of IgG and IgM antibodies to 2019 Novel Coronavirus in human whole
blood, serum or plasma.
CFUSSeries1000includes both antibody positive and negative reference materials. The positive is manufactured from human serum or plasma reactive for SARS-CoV-2IgG/IgM andnonreactiveforHBsAg and antibodies to HIV 1and 2, HTLV I and II, and HCV. There is a single vial of positive reference material (red cap) contained within each kit. The negative reference material is manufactured from human serum or plasma non-reactive for antibodies to SARS-CoV-2,aswellasHBsAgandantibodies to HIV 1 and 2, HTLV I and II, and HCV. There is a single vial of negative reference material (clear caps) contained within each kit. PACKAGE DETAIL:
Positive (Redcaps): 1x1.0mLvials Negative(Clearcaps): 1 x 1.0 ml vials This control contains stabilizers (EDTA, buffering agents), and 0.1% ProClin® (5- chloro-2-methyl- 4-isothiazolin-3-one & 2-methyl-4-isothiazolin-3-one) as preservative
This document provides information about the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit, which tests for antibodies to SARS-CoV-2, the virus that causes COVID-19. It discusses what COVID-19 is, how people are tested for it, what antibody tests are and their potential risks and benefits. It explains that positive, negative and false results are possible and how to interpret each result. It also notes that this test is authorized for emergency use by the FDA during the COVID-19 public health emergency.
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test KitsHK HuZef
LYHER Covid-19 IgG/IgM Antibody Rapid test Kits, US FDA EUA Approval Certificate.
This product, CFUS Anti-SARS-CoV-2 Reference Material Kit Series 1000, is formulated for use with the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit under the Emergency Use Authorization only.
Rapid diagnostic test for covid 19 may take around 10-20 minutes and are relatively simple to perform and interpret and therefore require limited test operator training. These slides illustrate the general concept of rapid test especially testing IgG and IgM antibodies against SARS-CoV-2 antigen .
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyHK HuZef
1. Accuracy
1.1 Purpose
To evaluate the equivalence of COVID-19 IgG/IgM Rapid Test result and clinical diagnosis.
1.2 Method
By testing clinical samples with known results, to evaluate the accuracy of COVID-19 IgG/IgM
Rapid Test (Whole blood/Serum/Plasma).
1.3 Material
COVID-19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma)
Cassette Lot1: 2002155,Lot2:2002156,Lot3:2002157
Clinical samples
1.4 Test Procedure
1) Prepare specimens: tests were taken to clinical partner to evaluate, totally 113 specimens.
2) Perform the test according to the test procedure in the package insert
1.5 Result
1) IgM
Risk Analysis of igg/igm Rapid Test Kits by healgenHK HuZef
1. Introduction
1.1. Overview
This document provides a safety risk analysis for COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma).
1.2. Intended Use/Purpose
COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a solid phase immunochromatographic
assay for the rapid, qualitative and differential detection of IgG and IgM antibodies to 2019 Novel Coronavirusi in
human whole blood, serum or plasma. This test provides only a preliminary test result. Therefore, any reactive
specimen with the COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) must be confirmed
with alternative testing method(s) and clinical findings.
1.3. Scope
This risk analysis addresses the safety risks that may affect the patient or the operator as associated with the
operation of the COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma).
This document provides a safety risk analysis for COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma), which references the standard of ISO 14971:2012.
buy Healgen Antibody IgG/IgM rapid test kitsHK HuZef
COVID-19 IgG/IgM Rapid Test
COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a solid
phase immunochromatographic assay for the rapid, qualitative and differential
detection of IgG and IgM antibodies to 2019 Novel Coronavirus in human whole
blood, serum or plasma.
CFUSSeries1000includes both antibody positive and negative reference materials. The positive is manufactured from human serum or plasma reactive for SARS-CoV-2IgG/IgM andnonreactiveforHBsAg and antibodies to HIV 1and 2, HTLV I and II, and HCV. There is a single vial of positive reference material (red cap) contained within each kit. The negative reference material is manufactured from human serum or plasma non-reactive for antibodies to SARS-CoV-2,aswellasHBsAgandantibodies to HIV 1 and 2, HTLV I and II, and HCV. There is a single vial of negative reference material (clear caps) contained within each kit. PACKAGE DETAIL:
Positive (Redcaps): 1x1.0mLvials Negative(Clearcaps): 1 x 1.0 ml vials This control contains stabilizers (EDTA, buffering agents), and 0.1% ProClin® (5- chloro-2-methyl- 4-isothiazolin-3-one & 2-methyl-4-isothiazolin-3-one) as preservative
This document provides information about the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit, which tests for antibodies to SARS-CoV-2, the virus that causes COVID-19. It discusses what COVID-19 is, how people are tested for it, what antibody tests are and their potential risks and benefits. It explains that positive, negative and false results are possible and how to interpret each result. It also notes that this test is authorized for emergency use by the FDA during the COVID-19 public health emergency.
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test KitsHK HuZef
LYHER Covid-19 IgG/IgM Antibody Rapid test Kits, US FDA EUA Approval Certificate.
This product, CFUS Anti-SARS-CoV-2 Reference Material Kit Series 1000, is formulated for use with the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit under the Emergency Use Authorization only.
Rapid diagnostic test for covid 19 may take around 10-20 minutes and are relatively simple to perform and interpret and therefore require limited test operator training. These slides illustrate the general concept of rapid test especially testing IgG and IgM antibodies against SARS-CoV-2 antigen .
This document summarizes laboratory diagnosis of COVID-19. It discusses that molecular (rRT-PCR) tests target genes like E, RdRp, N, and ORF 1ab. Specimens collected include nasopharyngeal swabs, oropharyngeal swabs, sputum, and stool. Interpretation of rRT-PCR tests follows WHO and CDC guidelines. Serological tests detect IgM and IgG antibodies but are not recommended for diagnosis. Viral sequencing and culture are also discussed. Abnormal lab findings in COVID-19 patients include decreased lymphocytes and albumin and increased LDH, D-dimer and inflammatory markers.
This document discusses diagnostic testing for COVID-19. It outlines that RT-PCR tests on respiratory samples are the reference standard, but point-of-care tests and serology are emerging. It recommends testing symptomatic individuals, healthcare workers, and those with recent exposure. Rapid antibody tests are not recommended for diagnosis but can indicate exposure. Specimens include respiratory and blood samples. Saliva samples may be a sensitive alternative to nasal swabs. Validation of diagnostic tests is important.
This document discusses diagnostic tests for COVID-19. It describes how samples are collected, typically nasopharyngeal or oropharyngeal swabs. Real-time reverse transcription polymerase chain reaction (RT-PCR) is the preferred testing method, using RNA extraction and fluorescent markers to detect viral DNA. Lateral flow and ELISA tests detect antibodies produced in response to infection. Treatment options discussed include chloroquine and favilavir. Several vaccine candidates are under development at universities and companies.
role serology in diagnosis and control of covid 19 shortPathKind Labs
- Serology testing can play an important role in the diagnosis and control of Covid-19 by detecting antibodies.
- While RT-PCR is still the gold standard for diagnosis, it has limitations such as being slow. Rapid antigen tests are rapid but not very sensitive.
- Serology tests can detect antibodies which begin appearing about 2 weeks after infection. They are useful for surveillance to understand spread and for identifying recovered individuals who may donate convalescent plasma.
This document provides an overview of laboratory diagnosis of AIDS, including:
1) The structure of HIV and the humoral and cellular immune response to HIV are described.
2) Diagnosis of AIDS involves antibody detection using screening tests like ELISA and confirmatory tests like Western blot. Antigen detection tests like p24 antigen capture and PCR are also used.
3) Laboratory monitoring of anti-retroviral therapy includes measuring CD4+ T cell counts, HIV RNA levels, and testing for HIV drug resistance.
1) The document describes an IgG/IgM rapid test cassette that uses a lateral flow immunochromatographic assay to detect antibodies in whole blood, serum, or plasma that are produced in response to COVID-19 infection.
2) The test works by detecting IgG and IgM antibodies that bind to COVID-19 antigens conjugated with colloid gold, which migrate through the cassette to test lines containing immobilized antibody. Positive results indicate recent or past COVID-19 infection.
3) The test cassette has received FDA Emergency Use Authorization as a qualitative detection tool to aid in identifying individuals with an adaptive immune response to COVID-19. However, clinical diagnosis requires consideration of additional factors and follow-up testing may
This document provides information on COVID-19 including its background, aetiology, symptoms, transmission, and methods of detection. It discusses COVID-19, caused by the SARS-CoV-2 virus, and describes its structure and entry into human cells. Symptoms are outlined and transmission primarily occurs through respiratory droplets. Detection methods covered include PCR, LAMP, whole genome sequencing, CRISPR-Cas and serologic tests like immunofluorescence assays, ELISA, and microneutralization assays. Advantages and disadvantages of each method are presented.
This document summarizes a seminar presentation on laboratory diagnosis of HIV. It discusses specimen collection, storage and transport. Screening tests covered include ELISA and rapid tests. Confirmatory tests discussed are Western blot and nucleic acid-based tests like PCR. Molecular assays for detecting HIV RNA are also summarized, including quantitative PCR and viral load determination. National testing strategies, reference laboratories, legal and ethical issues are also briefly covered.
1) Molecular testing for Covid-19 detection includes RT-PCR, TRUE NAT, and CB NAAT tests which detect viral RNA through nucleic acid amplification.
2) Antigen tests detect viral proteins and provide rapid results but have lower sensitivity than molecular tests.
3) Antibody tests detect antibodies produced after infection but cannot be used for diagnosis as they become positive later.
4) Newer modalities under research include multiplex assays, LAMP, CRISPR and other techniques for faster, portable, and higher-throughput Covid-19 testing.
The document discusses the application of polymerase chain reaction (PCR) in detecting infectious diseases. Specifically, it discusses:
1) PCR is a widely used nucleic acid amplification technique that can replicate a specific DNA region millions of times, allowing detection of small amounts of DNA or RNA from infectious pathogens.
2) PCR has revolutionized clinical infectious disease diagnosis by enabling rapid and accurate detection of viruses, bacteria, and other pathogens from patient samples.
3) The document provides examples of how PCR has been used to detect several infectious diseases, including hepatitis B, hepatitis C, human papillomavirus, HIV, influenza, and the novel coronavirus COVID-19.
The document discusses medical devices and in vitro diagnostics. It provides definitions and classifications of medical devices according to risk levels. It describes types of medical devices including diagnostic, therapeutic, and prosthetic devices. It discusses notified and non-notified in vitro diagnostic kits/reagents in India and examples. The regulation of medical devices in India is discussed along with the Drugs and Cosmetics Act. Manufacturers must comply with quality system regulations.
A Fully Automated Sample-to-result PCR System for Detecting Infectious DiseasesSimon Chung - genereach
This document describes GeneReach Biotechnology Corporation's POCKIT Central system, a fully automated sample-to-result PCR system for infectious disease detection. The POCKIT Central can detect multiple pathogens from a single sample in less than 2 hours, including dengue virus serotypes. It has been validated against qPCR with equivalent sensitivity and specificity for dengue virus detection and subtyping. The portable and easy-to-use POCKIT Central provides a rapid and accurate molecular diagnostic solution for point-of-care infectious disease testing.
Re-purposing ILRI labs to support national COVID-19 testing in KenyaILRI
Poster prepared by Edward Okoth and Samuel Oyola for the Global Agenda for Sustainable Livestock Africa 1 regional online meeting, 2-3 September 2020. Nairobi, Kenya: ILRI.
This document provides information about Tests For Life's COVID-19 IgM/IgG Rapid Antibody Test. The test is a point-of-care test that can detect both IgM and IgG antibodies in 10-15 minutes using a small blood sample without any instrumentation. It has a combined sensitivity of 100% and specificity of 98.75%. The document describes the test's applications, protocols, validation studies, packaging, and contact information for the company.
Rapid HIV tests can be performed outside laboratory settings using whole blood, saliva, or urine samples. They provide results within 20-40 minutes and do not require specialized equipment, electricity, or running water. Two common testing methods are serial testing, where two different rapid tests are used sequentially, and parallel testing, where two tests are run simultaneously on the same sample. A positive result requires counseling, while a negative result could mean the person is not infected or is in the early "window period" before antibodies form. Further testing is needed to confirm an initial positive or indeterminate result.
The document summarizes laboratory tests for diagnosing HIV infection. It describes the structure of the HIV virus and how it infects CD4+ T-cells. The main purposes of HIV testing are to prevent transmission through blood or from mother to child. HIV diagnosis involves screening assays like ELISA and rapid tests, followed by confirmatory tests like Western blot. Viral load and CD4 count are used to monitor disease progression. New techniques allow detection of HIV in alternative specimens like saliva, urine and oral fluids. Diagnosis in infants is challenging due to passive antibody transfer.
This document summarizes various laboratory tests used for HIV diagnosis and management. It describes enzyme immunoassays (EIAs) and rapid tests for detecting HIV antibodies. It also discusses tests for detecting the p24 antigen for early infant diagnosis, and CD4 and viral load tests for monitoring disease progression and response to antiretroviral therapy (ART). The document provides details on different formats of rapid tests including immuno-concentration, immuno-chromatography, and particle agglutination, and emphasizes the importance of proper training, supervision and monitoring for reliable HIV testing.
The COVID-19 pandemic, also known as the corona virus pandemic, is an ongoing pandemic of corona virus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome corona virus 2 (SARS‑CoV‑2).
Though several trials for candidate vaccines and potential therapies are underway, there is currently no cure, and in the absence of either proven effective therapy or a vaccine, diagnostic testing becomes a valuable tool. Testing is our window onto the pandemic and how it is spreading. Without data on who is infected by the virus we have no way of understanding the pandemic. Without this data we cannot know which countries are doing well, and which are just underreporting cases and deaths.
At IntellectPeritus, we have collected around 100 diagnostic kits (used in SARS-COV-2 diagnosis) and around 50 patent documents as sample report and have tried to put value added technology categories to generate specific insights quickly using our deliverable “Innovigence Corona”.
If you are interested in detailed or any customized report for SARS-COV-2 diagnostic kits please feel free to write to us at sales@intellectperitus.com
The document discusses laboratory diagnosis of HIV infection and its treatment. [1] Several specific tests are used to detect HIV infection including antigen detection, virus isolation, viral nucleic acid detection and antibody detection. [2] Non-specific tests like complete blood count and CD4/CD8 ratio are also used. [3] Opportunistic infections are diagnosed using microscopy, culture and specific tests. HIV treatment involves the use of several classes of antiretroviral drugs that target different stages of the viral lifecycle alone or in combination therapy.
COVID Testing and ICMR strategy and vaccinesRishikaThakur9
The document discusses COVID-19 testing strategies and vaccines in development in India. It provides details on appropriate specimen collection, storage and transport for COVID-19 testing. It outlines the types of COVID-19 tests - molecular, antigen and antibody - and provides guidance on using the different tests for various testing scenarios. It also summarizes the status of several COVID-19 vaccines in clinical trials in India, including Covishield, ZyCoV-D, Sputnik V and others.
This document summarizes laboratory diagnosis of COVID-19. It discusses that molecular (rRT-PCR) tests target genes like E, RdRp, N, and ORF 1ab. Specimens collected include nasopharyngeal swabs, oropharyngeal swabs, sputum, and stool. Interpretation of rRT-PCR tests follows WHO and CDC guidelines. Serological tests detect IgM and IgG antibodies but are not recommended for diagnosis. Viral sequencing and culture are also discussed. Abnormal lab findings in COVID-19 patients include decreased lymphocytes and albumin and increased LDH, D-dimer and inflammatory markers.
This document discusses diagnostic testing for COVID-19. It outlines that RT-PCR tests on respiratory samples are the reference standard, but point-of-care tests and serology are emerging. It recommends testing symptomatic individuals, healthcare workers, and those with recent exposure. Rapid antibody tests are not recommended for diagnosis but can indicate exposure. Specimens include respiratory and blood samples. Saliva samples may be a sensitive alternative to nasal swabs. Validation of diagnostic tests is important.
This document discusses diagnostic tests for COVID-19. It describes how samples are collected, typically nasopharyngeal or oropharyngeal swabs. Real-time reverse transcription polymerase chain reaction (RT-PCR) is the preferred testing method, using RNA extraction and fluorescent markers to detect viral DNA. Lateral flow and ELISA tests detect antibodies produced in response to infection. Treatment options discussed include chloroquine and favilavir. Several vaccine candidates are under development at universities and companies.
role serology in diagnosis and control of covid 19 shortPathKind Labs
- Serology testing can play an important role in the diagnosis and control of Covid-19 by detecting antibodies.
- While RT-PCR is still the gold standard for diagnosis, it has limitations such as being slow. Rapid antigen tests are rapid but not very sensitive.
- Serology tests can detect antibodies which begin appearing about 2 weeks after infection. They are useful for surveillance to understand spread and for identifying recovered individuals who may donate convalescent plasma.
This document provides an overview of laboratory diagnosis of AIDS, including:
1) The structure of HIV and the humoral and cellular immune response to HIV are described.
2) Diagnosis of AIDS involves antibody detection using screening tests like ELISA and confirmatory tests like Western blot. Antigen detection tests like p24 antigen capture and PCR are also used.
3) Laboratory monitoring of anti-retroviral therapy includes measuring CD4+ T cell counts, HIV RNA levels, and testing for HIV drug resistance.
1) The document describes an IgG/IgM rapid test cassette that uses a lateral flow immunochromatographic assay to detect antibodies in whole blood, serum, or plasma that are produced in response to COVID-19 infection.
2) The test works by detecting IgG and IgM antibodies that bind to COVID-19 antigens conjugated with colloid gold, which migrate through the cassette to test lines containing immobilized antibody. Positive results indicate recent or past COVID-19 infection.
3) The test cassette has received FDA Emergency Use Authorization as a qualitative detection tool to aid in identifying individuals with an adaptive immune response to COVID-19. However, clinical diagnosis requires consideration of additional factors and follow-up testing may
This document provides information on COVID-19 including its background, aetiology, symptoms, transmission, and methods of detection. It discusses COVID-19, caused by the SARS-CoV-2 virus, and describes its structure and entry into human cells. Symptoms are outlined and transmission primarily occurs through respiratory droplets. Detection methods covered include PCR, LAMP, whole genome sequencing, CRISPR-Cas and serologic tests like immunofluorescence assays, ELISA, and microneutralization assays. Advantages and disadvantages of each method are presented.
This document summarizes a seminar presentation on laboratory diagnosis of HIV. It discusses specimen collection, storage and transport. Screening tests covered include ELISA and rapid tests. Confirmatory tests discussed are Western blot and nucleic acid-based tests like PCR. Molecular assays for detecting HIV RNA are also summarized, including quantitative PCR and viral load determination. National testing strategies, reference laboratories, legal and ethical issues are also briefly covered.
1) Molecular testing for Covid-19 detection includes RT-PCR, TRUE NAT, and CB NAAT tests which detect viral RNA through nucleic acid amplification.
2) Antigen tests detect viral proteins and provide rapid results but have lower sensitivity than molecular tests.
3) Antibody tests detect antibodies produced after infection but cannot be used for diagnosis as they become positive later.
4) Newer modalities under research include multiplex assays, LAMP, CRISPR and other techniques for faster, portable, and higher-throughput Covid-19 testing.
The document discusses the application of polymerase chain reaction (PCR) in detecting infectious diseases. Specifically, it discusses:
1) PCR is a widely used nucleic acid amplification technique that can replicate a specific DNA region millions of times, allowing detection of small amounts of DNA or RNA from infectious pathogens.
2) PCR has revolutionized clinical infectious disease diagnosis by enabling rapid and accurate detection of viruses, bacteria, and other pathogens from patient samples.
3) The document provides examples of how PCR has been used to detect several infectious diseases, including hepatitis B, hepatitis C, human papillomavirus, HIV, influenza, and the novel coronavirus COVID-19.
The document discusses medical devices and in vitro diagnostics. It provides definitions and classifications of medical devices according to risk levels. It describes types of medical devices including diagnostic, therapeutic, and prosthetic devices. It discusses notified and non-notified in vitro diagnostic kits/reagents in India and examples. The regulation of medical devices in India is discussed along with the Drugs and Cosmetics Act. Manufacturers must comply with quality system regulations.
A Fully Automated Sample-to-result PCR System for Detecting Infectious DiseasesSimon Chung - genereach
This document describes GeneReach Biotechnology Corporation's POCKIT Central system, a fully automated sample-to-result PCR system for infectious disease detection. The POCKIT Central can detect multiple pathogens from a single sample in less than 2 hours, including dengue virus serotypes. It has been validated against qPCR with equivalent sensitivity and specificity for dengue virus detection and subtyping. The portable and easy-to-use POCKIT Central provides a rapid and accurate molecular diagnostic solution for point-of-care infectious disease testing.
Re-purposing ILRI labs to support national COVID-19 testing in KenyaILRI
Poster prepared by Edward Okoth and Samuel Oyola for the Global Agenda for Sustainable Livestock Africa 1 regional online meeting, 2-3 September 2020. Nairobi, Kenya: ILRI.
This document provides information about Tests For Life's COVID-19 IgM/IgG Rapid Antibody Test. The test is a point-of-care test that can detect both IgM and IgG antibodies in 10-15 minutes using a small blood sample without any instrumentation. It has a combined sensitivity of 100% and specificity of 98.75%. The document describes the test's applications, protocols, validation studies, packaging, and contact information for the company.
Rapid HIV tests can be performed outside laboratory settings using whole blood, saliva, or urine samples. They provide results within 20-40 minutes and do not require specialized equipment, electricity, or running water. Two common testing methods are serial testing, where two different rapid tests are used sequentially, and parallel testing, where two tests are run simultaneously on the same sample. A positive result requires counseling, while a negative result could mean the person is not infected or is in the early "window period" before antibodies form. Further testing is needed to confirm an initial positive or indeterminate result.
The document summarizes laboratory tests for diagnosing HIV infection. It describes the structure of the HIV virus and how it infects CD4+ T-cells. The main purposes of HIV testing are to prevent transmission through blood or from mother to child. HIV diagnosis involves screening assays like ELISA and rapid tests, followed by confirmatory tests like Western blot. Viral load and CD4 count are used to monitor disease progression. New techniques allow detection of HIV in alternative specimens like saliva, urine and oral fluids. Diagnosis in infants is challenging due to passive antibody transfer.
This document summarizes various laboratory tests used for HIV diagnosis and management. It describes enzyme immunoassays (EIAs) and rapid tests for detecting HIV antibodies. It also discusses tests for detecting the p24 antigen for early infant diagnosis, and CD4 and viral load tests for monitoring disease progression and response to antiretroviral therapy (ART). The document provides details on different formats of rapid tests including immuno-concentration, immuno-chromatography, and particle agglutination, and emphasizes the importance of proper training, supervision and monitoring for reliable HIV testing.
The COVID-19 pandemic, also known as the corona virus pandemic, is an ongoing pandemic of corona virus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome corona virus 2 (SARS‑CoV‑2).
Though several trials for candidate vaccines and potential therapies are underway, there is currently no cure, and in the absence of either proven effective therapy or a vaccine, diagnostic testing becomes a valuable tool. Testing is our window onto the pandemic and how it is spreading. Without data on who is infected by the virus we have no way of understanding the pandemic. Without this data we cannot know which countries are doing well, and which are just underreporting cases and deaths.
At IntellectPeritus, we have collected around 100 diagnostic kits (used in SARS-COV-2 diagnosis) and around 50 patent documents as sample report and have tried to put value added technology categories to generate specific insights quickly using our deliverable “Innovigence Corona”.
If you are interested in detailed or any customized report for SARS-COV-2 diagnostic kits please feel free to write to us at sales@intellectperitus.com
The document discusses laboratory diagnosis of HIV infection and its treatment. [1] Several specific tests are used to detect HIV infection including antigen detection, virus isolation, viral nucleic acid detection and antibody detection. [2] Non-specific tests like complete blood count and CD4/CD8 ratio are also used. [3] Opportunistic infections are diagnosed using microscopy, culture and specific tests. HIV treatment involves the use of several classes of antiretroviral drugs that target different stages of the viral lifecycle alone or in combination therapy.
COVID Testing and ICMR strategy and vaccinesRishikaThakur9
The document discusses COVID-19 testing strategies and vaccines in development in India. It provides details on appropriate specimen collection, storage and transport for COVID-19 testing. It outlines the types of COVID-19 tests - molecular, antigen and antibody - and provides guidance on using the different tests for various testing scenarios. It also summarizes the status of several COVID-19 vaccines in clinical trials in India, including Covishield, ZyCoV-D, Sputnik V and others.
Immunology lab manual for MLT students
Ethics of Laboratory
Collection of the blood sample by vein puncture, separation and preservation of serum
Widal Test
VDRL (including Antigen Preparation)
ASO (Anti streptolysin ‘O’)
C-Reactive Protein (Latex agglutination)
Rheumatoid factor (RF) Latex agglutination
Demonstration of antigen / antibody, determination by Immuno fluorescence (IF), Immuno diffusion, precipitation
in Agarose gel (Ouchterlony)
Demonstration of ELISA
Demonstration of SDS – PAGE
Preparation of Vaccination schedule
This document provides instructions for using the OneStep Tuberculosis (TB) RapiCardTM InstaTest, a rapid test for detecting anti-TB antibodies in whole blood, serum, or plasma. It is a qualitative two-site sandwich immunoassay that detects antibodies against recombinant TB antigens. The test procedure involves adding a blood, serum, or plasma specimen to the test cassette and reading the results after 10 minutes to identify positive or negative lines. A positive result indicates exposure to TB, while a negative result makes active TB less likely. The test performance was evaluated against smear/culture methods and shown to have 86.4% sensitivity and 99% specificity for TB diagnosis.
The document summarizes information about dengue virus, including that it is spread by Aedes mosquitoes during the day, there is no vaccine, and symptoms include fever, headaches, joint pain and rash. It describes dengue hemorrhagic fever as a serious condition affecting those previously infected with a different strain, and notes tests for dengue antibodies are performed at Liaquat National Hospital using an immunochromatographic kit called BIAS-3.
Ab find, an antibody test after covid 19 vaccination by meril lifeYashChopra43
Meril Life has created ABFind, India's first post-covid-19 vaccine antibody test kit. Here's where you can learn about home testing for fast neutralising antibodies.
This study evaluated three commercial rapid diagnostic tests for detecting typhoid fever in Vietnam: Multi-Test Dip-S-Ticks, TyphiDot and TUBEX. Blood samples were collected from 59 confirmed typhoid patients and 21 controls with other illnesses. The rapid tests showed sensitivities of 89%, 79% and 78% respectively, and specificities of 53%, 89% and 89%. The Widal test was less sensitive. TyphiDot and TUBEX which detect IgM antibodies performed best. However, the tests may detect past infections, so results should be interpreted cautiously. Further evaluation is needed to develop an ideal rapid typhoid diagnostic test.
1. ELISA (Enzyme-linked immunosorbent assay) is an immunoassay technique used to detect antibodies, proteins, peptides, and other molecules. It relies on an antigen-antibody reaction to detect the presence of a substance.
2. The document provides detailed information on the basic principles and steps of ELISA, including coating a plate with antibodies, adding samples and reagents, washing steps, and detecting reactions using enzymes and substrates.
3. Key aspects of performing ELISA are discussed such as sample treatment and storage, controlling humidity and air flow during incubations, and troubleshooting poor results. Direct, indirect, sandwich, and competitive ELISA techniques are also summarized.
This document provides instructions for using a Canine Leptospira Antibody Test Kit to determine a dog's antibody levels to Leptospira bacteria. The kit uses a comb-shaped plastic card to test serum samples in 12 wells for antibodies against 4 common Leptospira serovars. Results appear within 23 minutes as purple-grey dots on the comb, which are then compared to color standards to determine antibody levels and interpret as negative, low positive, or high positive based on a scale equivalent to common Leptospira antibody tests. The instructions provide details on sample collection and preparation, performing the test over multiple incubation steps, and interpreting results using the supplied color scale.
SARS-CoV-2 can be transmitted through respiratory droplets and aerosols from infected individuals. RT-PCR testing of nasopharyngeal and oropharyngeal swabs is the gold standard method for diagnosing COVID-19, though rapid antigen tests provide quick results. Diagnostic testing aims to identify infected individuals for isolation and treatment, trace their contacts, and determine when patients can end isolation. Symptomatic individuals, contacts of confirmed cases, and healthcare workers should be prioritized for testing.
The document discusses HIV/AIDS, including:
- HIV was identified as the cause of AIDS in 1983.
- HIV is transmitted through unprotected sex, contaminated blood, and from mother to child.
- India's HIV epidemic began in the 1980s, with over 2 million new infections globally in 2013.
- HIV diagnosis involves antibody and antigen tests, while treatment and monitoring involves CD4 counts and viral load tests.
Registration File of HBsAg Rapid Test (IHBSG-401&a_231225_120415) TA.docxqunhgiaonguynphm
This document provides information on an HBsAg rapid test dipstick/cassette that qualitatively detects the presence of HBsAg in whole blood, serum, or plasma. It works using a two-site sandwich immunoassay with monoclonal and polyclonal antibodies to detect HBsAg. The test yields a positive result if a colored line appears in the test region and a procedural control line is present. Performance characteristics such as accuracy, specificity, and stability are reported. Precautions for use and interpretation of results are also described.
This document discusses laboratory diagnosis of COVID-19. It describes how the disease spreads and appropriate sample types and collection methods. Molecular RT-PCR tests targeting SARS-CoV-2 genes like E, RdRp, N and ORF1ab are recommended for diagnosis. Serological and antigen tests can also be used but have limitations. Proper sample handling and accurate test interpretation are important for diagnosis. Laboratory networking is important for managing the COVID-19 pandemic.
Immunochromatographic assays, also known as lateral flow strip tests, allow for the rapid detection of antigens or antibodies in a sample within 15 minutes. The test works by utilizing two types of antibodies - one immobilized on the test strip and one labeled with a detectable marker like colloidal gold. When a sample is applied, it migrates up the strip via capillary action, allowing any antigens/antibodies in the sample to bind to the labeled antibodies and form complexes. These complexes are then captured by the immobilized antibodies, producing a visible test line that confirms the presence of the target antigen or antibody. Lateral flow tests are commercially available, easy to use, and provide results quickly with no specialized equipment,
This document provides information on syphilis serology testing. It discusses the stages of syphilis infection and describes the Venereal Disease Research Laboratory (VDRL) test. The VDRL test detects reagin antibodies produced in response to syphilis. The document outlines the principles, procedures, equipment needed and quality controls for performing the VDRL test to detect syphilis. It also notes potential causes of false negative VDRL results and limitations of the test.
The document discusses quality assurance in haemostasis laboratory testing. It outlines the importance of accuracy and precision in test results. There are three main types of quality assurance: internal quality control, external quality control, and participation in proficiency testing programs. The document also describes pre-analytic, analytic, and post-analytic factors that can affect test results and outlines standard operating procedures to ensure quality at each stage of testing. Maintaining reliable test results requires strict control of all variables from specimen collection through analysis and reporting.
1. There are two main types of tests for diagnosing syphilis - direct tests that detect the bacteria Treponema pallidum, and indirect serological tests that detect antibodies produced in response to the infection.
2. Direct tests include dark-field microscopy, direct fluorescent antibody testing, and PCR to identify the bacterium in lesions. Serological tests include non-treponemal tests like VDRL and RPR that detect nonspecific reagin antibodies, and treponemal tests like FTA-ABS, TPHA, and EIA that detect treponema-specific antibodies.
3. Dark-field microscopy examines exudate from lesions under a dark-field microscope to visualize
Care start access bio antigen test covid 19 biotechh commerceHafsaWadood1
The care start covid-19 antigen test is a lateral flow immuno-chromatographic assay, for the qualitative detect of the SARS coronavirus nucleo-capsid protein (major antigen). It is a rapid, easy, diagnostic test for the qualitative detection of Covid-19 antigen. This device is intended for use at Point of Care (POC) testing services.
collection and preservation of virus.pptxMawahbHatem
This document discusses clinical sample collection and preservation for virus detection. There are two types of virus samples: fluid samples like blood, serum, and urine, and solid samples like organs. When transporting specimens to the lab, they must be labeled and stored in viral transport media with ice or cold packs. Common specimens include blood, urine, stool, saliva, semen, eye secretions, CSF, cervical samples, and throat/nasal swabs. Viruses can be preserved long-term by freeze drying, storage in liquid nitrogen, or as purified nucleic acids at cold temperatures.
Similar to User Menual How To USE Covid-19 Antibody Tests By Healgen (20)
The interfering effects of biotin concentrations ranging between 625 ng/mL and 10 µg/mL were
tested in a separate study. Biotin concentrations up to 1.25 µg/ml did not lead to false results.
Biotin concentrations ≥2.5 µg/ml can cause false-negative COVID-19 results with the
CareStart™ COVID-19 Antigen.
High-dose Hook Effect
The CareStart™ COVID-19 Antigen was tested up to 105 TCID50/ml of heat-inactivated SARSCoV-2 strain and no high-dose hook effect was observed.
Point of Care Use
The CareStart™ COVID-19 Antigen was demonstrated at near patient or Point of Care (POC)
testing that non-laboratory personnel can perform the test accurately in the intended use
environment. In addition, the robust use of the CareStart™ COVID-19 Antigen for near patient
or Point of Care (POC) testing was demonstrated by thirteen (13) Flex studies.
Technical Support
For questions, or to report a problem, please call Technical Support at +1-888-898-1270
(Available Hours: Mon. to Fri.: 8 a.m. – 5 p.m.) or TShelp@accessbio.net (24/7 available).
Test system problems may also be reported to the FDA using the MedWatch reporting system
(phone: 1-800 FDA-1088; fax: 1-800 FDA-1078: or http://www.fda.gov/medwatch)
For Emergency Use Authorization (EUA) Only
The CareStartTM COVID-19 Antigen test is a lateral ow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2
in nasopharyngeal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider within ve days of symptom onset.
IMPORTANT!
- Refer to the Package Insert for Warnings and Precautions, Specimen Collection Procedures, Storage and Handling Conditions, and Quality Control Recommendations.
- Warning and Precautions - All kit components can be discarded as Biohazard waste according to local guidelines. Refer to the product safety data sheet for risk and safety phrases and disposal information.
- Biotin Interference: False negative results may occur in patients who have indicated or whose clinical status or history would indicate they are currently taking high doses of biotin (> 10 mg per day). Biotin
levels of 2.5 µg/mL have been demonstrated to result in false negative test results.
- The extracted sample must be used within 4 hours of preparation when stored at room temperature.
- Refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html
Access bio care antigen US=FDA EUA Approvel LetterHK HuZef
est Principles
The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal and nasal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers.
buy carestart covid-19 Antigen test by bio Access Inc, EUA Approvel Letter by...HK HuZef
The document provides instructions for using the CareStart COVID-19 Antigen rapid diagnostic test. It is a lateral flow test intended to qualitatively detect SARS-CoV-2 nucleocapsid protein antigen in nasopharyngeal swabs. The test involves extracting the swab in buffer, adding drops of extracted sample to the test cassette, and reading results at 10 minutes. Positive results require lines in both the test and control lines, while negative results have only a control line.
neoplex pcr test kit [genematrix]genematrix fda_eua -convertedHK HuZef
This letter provides an Emergency Use Authorization from the FDA to GeneMatrix, Inc. for their NeoPlex COVID-19 Detection Kit. The kit is authorized for qualitative detection of SARS-CoV-2 nucleic acid in upper and lower respiratory specimens from individuals suspected of COVID-19 by a healthcare provider. The authorization allows testing to be performed in CLIA certified laboratories. Numerous conditions are outlined for GeneMatrix, authorized distributors, and laboratories regarding product distribution, labeling, performance monitoring, and reporting of results.
neoplex pcr test kit [genematrix] declaration of conformity_rev00_neo_plex c...HK HuZef
This document declares that the NeoPlex COVID-19 Detection Kit, manufactured by GeneMatrix Inc., meets the requirements of the European Directive 98/79/EC for in vitro diagnostic medical devices. The declaration lists the manufacturer, product details including catalogue number and classification, standards applied, and is signed by the CEO of GeneMatrix Inc.
neoplex pcr test kit [genematrix advantages of neo_plex covid-19 Rapid Test K...HK HuZef
NeoPlexTM COVID-19 has advantages over PowerChek 2019-nCoV for PCR-based detection of COVID-19 including higher sensitivity detecting down to 10-5 compared to 10-3 for PowerChek, targeting two genes (RdRp and N) specific to COVID-19 versus one broadly reactive gene, and including an internal process control for nucleic acid extraction and PCR. NeoPlex also offers advantages of being more user-friendly, requiring fewer PCR machines, allowing testing of more samples per kit, and having longer shelf life and reagent stability.
costing and pricing of Covid-19 Rapid Test Kits in Nigeria complete indetaile...HK HuZef
We can supply 1 million COVID-19 test kits per day once orders are confirmed and paid. The document provides pricing details for test kits supplied in quantities from 25 pieces per box up to 40 million units. It also provides pricing and supply capacity for home treatment kits that include testing kits, protective equipment, and supplements to help contain the virus for those who test positive.
Covid-19 Best test Kits Official partners in Nigeria Rescue Technologies LimitedHK HuZef
Online Selling Authorized on www.covid-19besttestkits.com officially made a sucessful deal for the sale of covid-19 rapid home test with kits Nigeria Rescue Technologies Limited
Rapid test kits approved by NAFDAC
9 Furo Ezimora street
+2348066861218
+234 802 423 0993
Rescue Technologies Limited is a private Emergency ambulance Armed Response company. We provide low-cost subscription based 24/7 availability as well as location based dedicated ambulance.
During this global pandemic we are assisting government and other organizations by providing covid-19 Rapid Tests as well as all all PPE our prices are better than competitive and fair and we are committed to keeping that way but prices continue to rise and supplies will become limited due th3 global demand
B4u Bravo cabs services in Pakistan, complete presentation for driversHK HuZef
This document provides information about joining B4U Cabs as a driver or "Boss" in Pakistan. It summarizes the key benefits such as being your own boss, earning more money, and working flexible hours. It also outlines the application process which involves completing an online form, getting referred by another driver, or visiting an registration office. Required documents are also listed like a driving license, ID card, vehicle registration, and police clearance. Car categories are defined based on model, year, engine size, which determines fares. Daily bonus amounts are provided based on acceptance rate, hours logged, ratings received from rides. Reasons to join are noted such as cancellation time of 5 minutes and credit disbursement within 2 days
this is the presentation prepared by Mr Muhammad Huzaifa A PHD Scholar and Founder , CEO Of MITZ " Mansehra Information technology Zone" and this presenation explaining the complete idea about humen resource management software . Mitz is one of the leading pakistani IT Commpany
Sectional dentures for microstomia patients.pptxSatvikaPrasad
Microstomia, characterized by an abnormally small oral aperture, presents significant challenges in prosthodontic treatment, including limited access for examination, difficulties in impression making, and challenges with prosthesis insertion and removal. To manage these issues, customized impression techniques using sectional trays and elastomeric materials are employed. Prostheses may be designed in segments or with flexible materials to facilitate handling. Minimally invasive procedures and the use of digital technologies can enhance patient comfort. Education and training for patients on prosthesis care and maintenance are crucial for compliance. Regular follow-up and a multidisciplinary approach, involving collaboration with other specialists, ensure comprehensive care and improved quality of life for microstomia patients.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
English Drug and Alcohol Commissioners June 2024.pptxMatSouthwell1
Presentation made by Mat Southwell to the Harm Reduction Working Group of the English Drug and Alcohol Commissioners. Discuss stimulants, OAMT, NSP coverage and community-led approach to DCRs. Focussing on active drug user perspectives and interests
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Mental Health and well-being Presentation. Exploring innovative approaches and strategies for enhancing mental well-being. Discover cutting-edge research, effective strategies, and practical methods for fostering mental well-being.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
nurs fpx 4050 assessment 4 final care coordination plan.pdf
User Menual How To USE Covid-19 Antibody Tests By Healgen
1. 1
Cat: GCCOV-402a
For Emergency Authorization Use (EUA) only
For in vitro diagnostic use only
For prescription use only
INTENDED USE
The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is
a lateral flow immunoassay intended for the qualitative detection and differentiation
of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood, plasma
from anticoagulated blood (Li+ heparin, K2EDTA and sodium citrate), or
serum. The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)
is intended for use as an aid in identifying individuals with an adaptive immune
response to SARS-CoV-2, indicating recent or prior infection. At this time, it is
unknown for how long antibodies persist following infection and if the presence of
antibodies confers protective immunity. The COVID-19 IgG/IgM Rapid Test
Cassette (Whole Blood/Serum/Plasma) should not be used to diagnose acute
SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform
moderate or high complexity tests.
Results are for the detection of SARS CoV-2 antibodies. IgM and IgG antibodies to
SARS-CoV-2 are generally detectable in blood several days after initial infection,
although the duration of time antibodies are present post-infection is not well
characterized. Individuals may have detectable virus present for several weeks
following seroconversion.
Laboratories within the United States and its territories are required to report all
positive results to the appropriate public health authorities.
The sensitivity of COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) early after infection in unknown. Negative results do not
preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing
for SARS-CoV-2 is necessary.
False positive results for COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) may occur due to cross-reactivity from pre-existing
antibodies or other possible causes. Due to the risk of false positive results,
confirmation of positive results should be considered using second, different IgG or
IgM assay.
The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is only
for use under the Food and Drug Administration’s Emergency Use Authorization.
INTRODUCTION
Coronaviruses are enveloped RNA viruses that are distributed broadly among
humans, other mammals, and birds and that cause respiratory, enteric, hepatic,
and neurologic diseases. Seven coronavirus species are known to cause human
disease. Four viruses - 229E, OC43, NL63, and HKU1 - are prevalent and typically
cause common cold symptoms in immunocompetent individuals.4 The three other
strains - severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East
respiratory syndrome coronavirus (MERS-CoV) and 2019 Novel Coronavirus
(COVID-19) - are zoonotic in origin and have been linked to sometimes fatal illness.
IgG and IgM antibodies to 2019 Novel Coronavirus can be detected with 1-3 weeks
after exposure. The seroconversion rate and the antibody levels increased rapidly
during the first two weeks.
PRINCIPLE
The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a
lateral flow immunochromatographic assay. The test uses anti-human IgM antibody
(test line IgM) , anti-human IgG (test line IgG) and rabbit IgG (control line C)
immobilized on a nitrocellulose strip. The burgundy colored conjugate pad contains
colloidal gold conjugated to recombinant COVID-19 antigens (SARS-CoV-2 Spike
S1 antigen) conjugated with colloid gold (COVID-19 conjugates). When a specimen
followed by assay buffer is added to the sample well, IgM &/or IgG antibodies if
present, will bind to COVID-19 conjugates making an antigen antibodies complex.
This complex migrates through nitrocellulose membrane by capillary action. When
the complex meets the line of the corresponding immobilized antibody (anti-human
IgM &/or anti-human IgG) the complex is trapped forming a burgundy colored band
which confirms a reactive test result. Absence of a colored band in the test region
indicates a non-reactive test result.
To serve as a procedural control, a colored line will always change from blue to red
in the control line region, indicating that the proper volume of specimen has been
added and membrane wicking has occurred.
MATERIALS SUPPLIED
25 sealed pouches each containing a test cassette, a dropper and a desiccant
1 Buffer
1 Package insert
MATERIAL REQUIRED BUT NOT PROVIDED
1. Specimen collection containers
2. Centrifuge (for plasma only)
3. Timer
STORAGE AND STABILITY
The kit can be stored at room temperature or refrigerated (2-30°C). The test device
is stable through the expiration date printed on the sealed pouch. The test device
must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond
the expiration date.
WARNINGS AND PRECAUTIONS
1. For professional in vitro diagnostic use only. Do not use after expiration date.
2. Use of this product is limited to laboratories certified under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to
perform moderate or high complexity tests.
3. This test should be performed at 15 to 30℃. If stored refrigerated, ensure that
the pouch and buffer are brought to operating temperature before performing
testing.
4. This package insert must be read completely before performing the test.
Failure to follow the insert gives inaccurate test results.
5. Do not use it if the tube/pouch is damaged or broken.
6. Test is for single use only. Do not re-use under any circumstances.
7. Handle all specimens as if they contain infectious agents. Observe established
precautions against microbiological hazards throughout testing and follow the
standard procedures for proper disposal of specimens.
8. Wear protective clothing such as laboratory coats, disposable gloves and eye
protection when specimens are assayed.
9. Humidity and temperature can adversely affect results (especially with an RH
over 80%). Testing must be performed within one hour after opening the
pouch .
10. Do not perform the test in a room with strong air flow, ie. electric fan or strong
air-conditioning.
11. Practice a few times the use of the mini dropper prior to testing if you are not
familiar with the mini dropper. For better precision, transfer specimen by
pipette capable to deliver 5 µL of volume.
COVID-19 IgG/IgM Rapid Test Cassette
(Whole Blood/Serum/Plasma)
Instruction for Use
In Vitro Diagnostic Medical Device
2. 2
12. This test has not been FDA cleared or approved.
13. This test has been authorized by FDA under an EUA for use by authorized
laboratories.
14. This test has been authorized only for the presence of IgM and IgG antibodies
against SARS-CoV-2, not for any other viruses or pathogens.
15. This test is only authorized for the duration of the declaration that
circumstances exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1)
of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or
revoked sooner.
SPECIMEN COLLECTION
1. COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) can be
performed using either venous whole blood, serum or plasma.
2. The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)
test has not been evaluated with fingerstick specimens. Use of this test with
fingerstick blood is not recommended.
3. Separate serum or plasma from blood as soon as possible to avoid hemolysis.
Use only clear, non-hemolyzed specimens.
4. Testing should be performed immediately after specimen collection. Do not
leave the specimens at room temperature for prolonged periods. Serum and
plasma specimens may be stored at 2-8°C for up to 3 days. For long term
storage, specimens should be kept below -20°C for up to one month. Whole
blood specimens must be stored at 2-8˚C if not tested immediately and tested
within 24 hours of collection. Do not freeze whole blood specimens.
5. Bring specimens to room temperature prior to testing. Frozen specimens must
be completely thawed and mixed well prior to testing. Specimens cannot be
frozen and thawed more than 3 times.
6. If specimens are to be shipped, they should be packed in compliance with local
regulations covering the transportation of etiologic agents.
TEST PROCEDURE
Allow test cassette, specimen, buffer and/or controls to equilibrate to room
temperature (15-30°C) prior to testing.
1. Remove the test cassette from the sealed foil pouch and use it as soon as
possible. Results must be obtained within one hour.
2. Place the test device on a clean and level surface.
For Serum or Plasma Specimens:
With a 5 µL mini plastic dropper provided, draw serum/plasma specimen to
exceed the specimen line as showed in the following image and then transfer
drawn serum/plasma specimen into the sample well (S). Then add 2 drops
(about 80 µL) of sample buffer to the buffer well (B) immediately. Avoid air
bubbles.
Note: Practice a few times prior to testing if you are not familiar with the mini
dropper. For better precision, transfer specimen by pipette capable to
deliver 5 µL of volume.
For Venous Whole Blood Specimen:
Hold the 5 µL mini plastic dropper vertically and transfer 1 drop of whole blood
(about 10 µL) to the specimen well (S) of the test device, then add 2 drops
(about 80 µL) of sample buffer to the buffer well (B) immediately. Avoid air
bubbles.
3. Wait for the colored line(s) to appear. After 2 minutes, if the red color has not
moved across the test window or if blood is still present in the specimen well
(S), add 1 additional drop of the sample buffer to the buffer well (B).
4. The result should be read in 10 minutes. Positive results may be visible as
soon as 2 minutes. Do not interpret the result after 15 minutes.
INTERPRETATION OF RESULTS
NEGATIVE:
The colored line in the control line region (C) changes from blue to red. No line
appears in the test line regions M or G. The result is negative.
IgM POSITIVE:
The colored line in the control line region (C) changes from blue to red, and a
colored line appears in test line region M. The test result indicates the presence of
IgM anti-SARS-Cov-2 antibodies.
IgG POSITIVE:
The colored line in the control line region (C) changes from blue to red, and a
colored line appears in test line region G. The test result indicates the presence of
IgG anti-SARS-CoV-2 antibodies
IgG and IgM POSITIVE:
The colored line in the control line region (C) changes from blue to red, and two
colored lines appear in test line regions M and G. The test results indicate the
presence of IgM and IgG anti-SARS-CoV-2 antibodies.
INVALID:
Control line is partially red, and fails to completely change from blue to red.
Insufficient specimen volume or incorrect procedural techniques are the most likely
reasons for control line failure. Review the procedure and repeat the test with a
new test cassette. If the problem persists, discontinue using the test kit immediately
and contact your local distributor.
QUALITY CONTROL
A procedural control is included in the test. A red line appearing in the control
region (C) is the internal procedural control. It confirms sufficient specimen volume
and correct procedural technique.
Control standards are not supplied with this kit; however, it is recommended that
positive and negative controls be tested as a good laboratory practice to confirm
the test procedure and to verify proper test performance. Additional controls may
be required according to guidelines or local, state, and/or federal regulations (such
as 42 CFR 493.1256) or accrediting organizations.
LIMITATIONS
For use under an Emergency Use Authorization only.
1. Use of COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)
is limited to laboratory personnel who have been trained. Not for home use.
2. This product is only used for testing of individual serum, plasma (Li+ heparin,
K2EDTA and sodium citrate), and venous whole blood. Other specimen types
have not been evaluated and should not be used with this assay.
3. Use fresh samples whenever possible. Frozen and thawed samples
(especially repeatedly) contain particles that can block the membrane. This
slows the flow of reagents and can lead to high background color, making the
interpretation of results difficult.
4. The Assay Procedure and the Interpretation of Assay Result must be followed
closely when testing for the presence of SARS-CoV-2 virus specific antibodies
in the serum, plasma or whole blood specimen from individual subjects. For
optimal test performance, proper sample collection is critical. Failure to follow
the procedure may give inaccurate results.
5. Reading test results earlier than 10 minutes after the addition of Buffer may
yield erroneous results. Do not interpret the result after 15 minutes.
6. This test detects the presence of SARS-CoV-2 IgM/IgG in the specimen and
should not be used to diagnose or exclude SARS-CoV-2 infection. Testing with
3. 3
a molecular diagnostic must be performed to evaluate for active infection in
symptomatic individuals.
7. It is not known at this time if the presence of antibodies to SARS-CoV-2
confers immunity to re-infection.
8. A positive result may not indicate previous SARS-CoV-2 infection. Consider
other information, including clinical history and local disease prevalence, in
assessing the need for a second but different serology test to confirm an
adaptive immune response.
9. A negative result for an individual subject indicates absence of detectable
anti-SARS-CoV-2 antibodies. Negative results do not preclude SARS-CoV-2
infection and should not be used as the sole basis for patient management
decisions. IgM antibodies may not be detected in the first few days of infection;
the sensitivity of the COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) early after infection is unknown. False positive results
for IgM and IgG antibodies may occur due to cross-reactivity from pre-existing
antibodies or other possible causes. Samples with positive results should be
confirmed with alternative testing method(s) and clinical findings before a
diagnostic determination is made. A negative result can occur if the quantity of
the anti-SARS-CoV-2 antibodies present in the specimen is below the
detection limits of the assay, or the antibodies that are detected are not
present during the stage of disease in which a sample is collected.
10. Some specimens containing unusually high titer of heterophile antibodies or
rheumatoid factor may affect expected results.
11. The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is
limited to the qualitative detection of antibodies specific for the SARS-CoV-2
virus. The intensity of the test line does not necessarily correlate to
SARS-CoV-2 antibody titer in the specimen. Neither the quantitative value nor
the rate anti- SARS-CoV-2 IgM/IgG concentration can be determined by this
qualitative test.
12. The sensitivity of the test is impacted after being open for two hours—the
density of T line becomes weak. Testing must be performed within one hour
after opening the pouch.
CONDITIONS OF AUTHORIZATION FOR THE LABORATORY
The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) Letter
of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the
authorized Fact Sheet for Recipients, and authorized labeling are available on the
FDA website:
https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emerg
ency-use-authorizations#covid19ivd.
Authorized laboratories using the COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) (“your product” in the conditions below), must adhere to the
Conditions of Authorization indicated in the Letter of Authorization as listed below:
1. Authorized laboratories* using your product will include with result
reports of your product, all authorized Fact Sheets. Under exigent
circumstances, other appropriate methods for disseminating these Fact
Sheets may be used, which may include mass media
2. Authorized laboratories using your product will use your product as
outlined in the Instructions for Use. Deviations from the authorized
procedures, including the authorized clinical specimen types,
authorized control materials, authorized other ancillary reagents and
authorized materials required to use your product are not permitted.
3. Authorized laboratories that receive your product will notify the relevant
public health authorities of their intent to run your product prior to
initiating testing.
4. Authorized laboratories using your product will have a process in place
for reporting test results to healthcare providers and relevant public
health authorities, as appropriate.
5. Authorized laboratories will collect information on the performance of
your product and report to DMD/OHT7-OIR/OPEQ/ CDRH (via email:
CDRH-EUA-Reporting@fda.hhs.gov) and Healgen Scientific LLC
(info@healgen.us) any suspected occurrence of false reactive or false
non-reactive results and significant deviations from the established
performance characteristics of your product of which they become
aware.
6. All laboratory personnel using your product must be appropriately
trained in immunoassay techniques and use appropriate laboratory and
personal protective equipment when handling this kit and use your
product in accordance with the authorized labeling. All laboratory
personnel using the assay must also be trained in and be familiar with
the interpretation of results of the product
7. Authorized distributors, and authorized laboratories using your product
will ensure that any records associated with this EUA are maintained
until otherwise notified by FDA. Such records will be made available to
FDA for inspection upon request.
*The letter of authorization refers to, “Laboratories certified under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to
perform moderate or high complexity tests” as “authorized laboratories.”
PERFORMANCE CHARACTERISTICS
1. Assay Clinical Performance
Study 1: Healgen Clinical Agreement Validation
The clinical performance of the COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) was evaluated by testing a total of 191 plasma (K2EDTA)
clinical samples—90 positive samples and 101 negative samples) from individual
patients exhibiting pneumonia, respiratory symptoms and fever etc. Testing was
performed at two sites in China from January to mid-March 2020. COVID-19
IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) results for IgM and IgG
detection were compared to the results of RT-PCR assays for SARS-CoV-2 from
oropharyngeal swabs (Site #1) and sputum (Site #2). At Site #1, 61 retrospective
specimens and 4 prospective specimens were included in the study. At Site #2, 95
retrospective specimens and 31 prospective specimens were included in the study.
The time from RT-PCR result to collection of specimens (plasma) ranged from
15-45 days (Site #1) and 0-38 days (Site #2). The time from collection of specimens
(plasma) from each individual to testing ranged from 12-23 days (Site #1) and 3-29
days (Site #2). Overall study results are shown in below (Table 1).
Table 1: Assay Clinical Study Results
Method
RT-PCR
Subtotal
Positive Negative
COVID-19
IgG/IgM
Rapid Test
Cassette
Positive
IgG+/IgM+ 78 0 78
IgG-/IgM+ 0 1 1
IgG+/IgM- 9 2 11
Negative IgG-/IgM- 3 98 101
Subtotal 90 101 191
IgG
Positive Percent agreement (PPA): 96.7% (87/90) (95%CI: 90.7%~98.9%) Negative
Percent agreement (NPA): 98.0% (99/101) (95%CI: 93.1%~99.5%)
IgM
Positive Percent agreement (PPA): 86.7% (78/90) (95%CI: 78.1%~92.2%) Negative
Percent agreement (NPA): 99.0% (100/101) (95%CI: 94.6%~99.8%)
Overall (either IgG+ or IgM+)
Positive Percent agreement (PPA): 96.7% (87/90) (95%CI: 90.7%~98.9%) Negative
Percent agreement (NPA): 97.0% (98/101) (95%CI: 91.6%~99.0%)
Study 2: Independent Clinical Agreement Validation
The test was validated against a panel of previously frozen samples consisting of
30 SARS-CoV-2 antibody-positive serum samples and 80 antibody-negative serum
and plasma samples. Each of the 30 antibody-positive samples were confirmed
with a nucleic acid amplification test (NAAT) and both IgM and IgG antibodies were
confirmed to be present in all 30 samples. The presence of antibodies in the
samples was confirmed by several orthogonal methods prior to testing with the
COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma). The
presence of IgM and IgG antibodies specifically was confirmed by one or more
comparator methods. Antibody-positive samples were selected at different
antibody titers.
All antibody-negative samples were collected prior to 2020 and include: i) Seventy
(70) samples selected without regard to clinical status, “Negatives” and ii) Ten (10)
samples selected from banked serum from HIV+ patients, “HIV+”. Testing was
performed by one operator using one lot of the COVID-19 IgG/IgM Rapid Test
Cassette (Whole Blood/Serum/Plasma). Confidence intervals for sensitivity and
specificity were calculated per a score method described in CLSI EP12-A2 (2008).
For evaluation of cross-reactivity with HIV+, it was evaluated whether an increased
false positive rate among antibody-negative samples with HIV was statistically
higher than the false positive rate among antibody-negative samples without HIV
(for this, a confidence interval for the difference in false positive rates was
calculated per a score method described by Altman). The results and data analysis
are shown in the tables below.
Table 2. Summary Results
COVID-19 IgG/IgM Rapid Test
Comparator Method
4. 4
Cassette (Whole
Blood/Serum/Plasma)
Positive
(IgM/IgG) +
Negative
(IgM/IgG)-
Negative,
HIV+
Total
Positive
IgM +/ IgG+ 29 0 0 29
IgM+, IgG- 1 0 0 1
IgM-, IgG+ 0 2 0 2
Negative IgM- / IgG)- 0 68 10 78
Total (n=110) 30 70 10 110
Table 3. Summary Statistics
Measure Estimate
Confidence
Interval
IgM Sensitivity 100% (30/30)
(88.7%;
100%)
IgG Sensitivity 96.7% (29/30)
(83.3%;
99.4%)
(IgM+ or IgG+; Total) Sensitivity (PPA) 100% (30/30)
(88.7%;
100%)
(IgM-/IgG-; Total) Specificity (NPA) 97.5% (78/80)
(91.3%;
99.3%)
Cross-reactivity with HIV+
0% (0/10)
not detected
Limitations of Study 2
• Samples were not randomly selected, and sensitivity and specificity estimates
may not be indicative of the real-world performance of the device.
• These results are based on serum and plasma samples only and may not be
indicative of performance with other sample types, such as whole blood,
including finger stick blood.
• Information about anticoagulants used is not known.
• The number of samples in the panel is a minimally viable sample size that still
provides reasonable estimates and confidence intervals for test performance,
and the samples used may not be representative of the antibody profile
observed in patient populations.
2. Assay Cross Reactivity
Cross-reactivity of the COVID-19 IgG/IgM Rapid Test (Whole Blood/Serum/Plasma)
was evaluated using serum samples which contain antibodies to the pathogens
listed below. A total of 120 specimens from 24 different categories were tested. No
false Positives were found with the following (Table 4):
Table 4: Assay Cross Reactivity Results
Sample Categories Tested Sample Number
Influenza A virus IgG 5
Influenza B virus IgG 5
Respiratory syncytial virus IgG 5
Adenovirus IgG 5
Rhinovirus IgG 5
Human metapneumovirus IgG 5
Mycoplasma pneumoniae IgG 5
Chlamydia pneumoniae IgG 5
HCV IgG 5
Haemophilus influenza IgG 5
HBV core antibody IgG 5
Bacterial pneumonia 5
Influenza A virus IgM 5
Influenza B virus IgM 5
Respiratory syncytial virus IgM 5
Adenovirus IgM 5
Rhinovirus IgM 5
Human metapneumovirus IgM 5
Mycoplasma pneumoniae IgM 5
Chlamydia pneumoniae IgM 5
HCV IgM 5
Haemophilus influenza IgM 5
HBV core antibody IgM 5
Antinuclear antibodies (ANA) 5
3. Potentially Endogenous Interfering Substances
Low titer COVID-19 antibody positive serum samples and COVID-19 antibody
negative serum samples were spiked with one of the following substances to
specified concentrations and tested in multiple replicates. No false Positives or
false Negatives were found with the following (Table 5).
Table 5: Assay Interfering Substance Results
Name of Substances Concentration
Ascorbic Acid 20 mg/dL
Hemoglobin 1000 mg/dL
Bilirubin 10 mg/dL
Albumin 2000 mg/dL
Triglyceride 500 mg/dL
4. Class Specificity
A Class Specificity Study was conducted to determine the impact of DTT
treatment on the detection of IgM and/or IgG positive samples by the
COVID-19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma). IgM
samples treated with DTT showed no visible IgM line with the COVID-19
IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma), whereas the
IgG samples were not affected by DTT treatment. Test results with IgM
positive samples after DTT treatment showed 100% agreement to the
expected results. Test results with IgG positive samples after DTT treatment
showed 100% agreement to the expected results. The results observed
confirm the class specificity of the test.
5. Study of: Venous Whole Blood and Plasma Specimens with
Anticoagulants
To evaluate if various anticoagulants have an effect on the results of the
COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma),
negative plasma specimens and positive plasma specimens (with 2 different
low positive IgG and IgM concentrations) were mixed with three different
anticoagulants (lithium heparin, EDTA, sodium citrate) in separate tubes
and tested in triplicate in plasma only or spiked into venous whole blood.
IgG and IgM were correctly identified in all spiked whole blood specimens
by the test, similar to results obtained with the plasma only specimens.
There was a 100% concordance rate with expected results when IgM or IgG
positive venous whole blood specimens or plasma specimens were tested
with anticoagulants.
REFERENCE:
1. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011; 81:
85-164.
2. Masters PS, Perlman S. Coronaviridae. In: Knipe DM, Howley PM, eds. Fields
virology. 6th ed. Lippincott Williams & Wilkins, 2013: 825-58.
3. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and
pathogenesis of coronaviruses. Trends Microbiol 2016; 24: 490-502.
4. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev
Microbiol 2019; 17: 181-192.
Manufactured for:
Healgen Scientific LLC
Address: 3818 Fuqua Street,
Houston, TX 77047, USA.
Tel: +1 713-733-8088
Fax: +1 713-733-8848
Website: www.healgen.com
Revision Date: 2020-5-2